Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
QU QURE uniQure N.V. FY ended Feb 26, 2026 | $48.72 | $3.07B | $3.55B | $16.10M | -$142.68M | -$198.97M | -14.08x | 190.87x | — |
SR SRPT Sarepta Therapeutics, Inc. FY ended Feb 24, 2026 | $20.86 | $2.20B | $2.78B | $2.20B | -$686.34M | -$713.41M | -2.93x | 1.00x | — |
RG RGNX REGENXBIO Inc. FY ended Feb 27, 2026 | $9.66 | $637.69M | $690.20M | $170.44M | -$187.17M | -$193.88M | -2.57x | 3.74x | — |
RA RARE Ultragenyx Pharmaceutical Inc. FY ended Feb 13, 2026 | $25.61 | $2.52B | $2.37B | $673.00M | -$571.00M | -$575.00M | -4.39x | 3.75x | — |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | — | 0/4 | — | — | No saved peers have usable coverage for this method. |
Price / Sales PSActive | Equity Multiple | 49.84x | 4/4 | $19.39B | $655.26 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -5.99x | 4/4 | -$1.23B | — | Peer averages are not economically meaningful for this method. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
QU QURE uniQure N.V. FY ended Feb 26, 2026 | $48.72 | $3.07B | $3.55B | $16.10M | -$142.68M | -$198.97M | -14.08x | 190.87x | — |
SR SRPT Sarepta Therapeutics, Inc. FY ended Feb 24, 2026 | $20.86 | $2.20B | $2.78B | $2.20B | -$686.34M | -$713.41M | -2.93x | 1.00x | — |
RG RGNX REGENXBIO Inc. FY ended Feb 27, 2026 | $9.66 | $637.69M | $690.20M | $170.44M | -$187.17M | -$193.88M | -2.57x | 3.74x | — |
RA RARE Ultragenyx Pharmaceutical Inc. FY ended Feb 13, 2026 | $25.61 | $2.52B | $2.37B | $673.00M | -$571.00M | -$575.00M | -4.39x | 3.75x | — |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | — | 0/4 | — | — | No saved peers have usable coverage for this method. |
Price / Sales PSActive | Equity Multiple | 49.84x | 4/4 | $19.39B | $655.26 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -5.99x | 4/4 | -$1.23B | — | Peer averages are not economically meaningful for this method. |
